The Changing CDMO Landscape: Single-Use Technology, End-to-End Fill Finish Needs and Growth of Cell and Gene

Feature
Video

Sponsored Video

Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.

Watch this video to learn more:

  • AGC Biologics’ new fill and finish offering for protein biologics
  • Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
  • The power of single-use technology for developers
  • The CDMOs growing cell and gene commercial track record

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
© 2025 MJH Life Sciences

All rights reserved.